About us
Our projects
About cancer
Investors
News and media
Connect
Svenska

Medivir in brief
Business concept & Strategy
Leadership
- Management team
- Board of Directors
History
EFPIA Disclosure

Proprietary
- Fostroxacitabine bralpamide (fostrox)
Projects for licensing
- Remetinostat
- MIV-711
Partnerships
Publications

About cancer

Stock information
Reports
Presentations
Press releases
Calendar
Corporate Governance
General Meetings
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
Rights issue 2023

Press releases
Media bank
Subscribe to Press Releases

Connect with Medivir
Partner with Medivir

Back to archive

Events2024/11/06

Interim Report, January - September 2024 (webcast)

Address

Medivir AB
Box 1086
SE-141 22 Huddinge
Visit: Lunastigen 5, 2nd floor

Phone +46 (0)8 5468 31 00 Email info@medivir.com

Our privacy policy

Jens Lindberg

Chief Executive Officer

jens.lindberg@medivir.com

Magnus Christensen

Chief Financial Officer

magnus.christensen@medivir.com